---
document_datetime: 2025-12-02 05:08:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tukysa.html
document_name: tukysa.html
version: success
processing_time: 0.1102615
conversion_datetime: 2025-12-28 11:42:10.990419
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tukysa

[RSS](/en/individual-human-medicine.xml/67413)

##### Authorised

This medicine is authorised for use in the European Union

tucatinib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Tukysa](#news-on)
- [More information on Tukysa](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Tukysa is a cancer medicine that is used to treat breast cancer that is locally advanced or metastatic (has spread to other parts of the body) and when it is HER2-positive. This means the cancer cells produce a protein on their surface, HER2, which stimulates the growth of the cancer.

Tukysa is used with two other medicines, capecitabine and trastuzumab, and is used after at least 2 other treatments for HER2-positive cancer have already been tried.

The active substance in Tukysa is tucatinib.

Expand section

Collapse section

## How is Tukysa used?

Tukysa can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in giving cancer treatments. It is given by mouth in a recommended dose of 300 mg twice a day. Patients are also treated with capecitabine and trastuzumab on certain days of a 21-day cycle.

Treatment can continue as long as the cancer does not get worse and side effects are bearable. The doctor may recommend a reduced dose of Tukysa if certain side effects occur, or may stop treatment temporarily or permanently.

For more information about using Tukysa, see the package leaflet or contact your doctor.

## How does Tukysa work?

The active substance in Tukysa, tucatinib, is a type of cancer medicine called a tyrosine kinase inhibitor. It attaches to the HER2 protein on the cancer cells, and so blocks its action. Because HER2 helps cancer cells to grow and divide, blocking it helps to stop these cells growing and causes them to die, controlling the growth of the cancer.

## What benefits of Tukysa have been shown in studies?

Tukysa has been shown to improve the length of time that patients with advanced or metastatic HER2-positive breast cancer lived without their disease getting worse. In an ongoing main study involving 612 such patients whose disease had got worse after previous treatments or in whom other treatments were unsuitable, Tukysa was compared with placebo (a dummy treatment) when added to two other cancer medicines, trastuzumab and capecitabine.

When the results were analysed, the average length of time that patients lived without their disease getting worse was 7.8 months with Tukysa and 5.6 months with placebo. Overall, around 41% of patients given Tukysa and 23% given placebo showed some response to treatment and the two groups lived on average about 22 months and 17 months respectively. Responses to Tukysa were comparable in the subgroup of patients whose cancer had spread to the brain.

## What are the risks associated with Tukysa?

The most common side effects with Tukysa (which may affect more than 1 in 10 people) are nose bleeds, diarrhoea, nausea (feeling sick), vomiting, stomatitis (inflammation of the mouth), rash, arthralgia (joint pain), increases in the blood levels of liver enzymes ALT and AST (a sign of potential liver problems) and in bilirubin, and weight loss. The most common serious side effects with Tukysa (which may affect more than 1 in 20 people) are diarrhoea and increased ALT and AST; nausea and vomiting may also be serious.

For the full list of side effects and restrictions with Tukysa, see the package leaflet.

## Why is Tukysa authorised in the EU?

The European Medicines Agency noted that the evidence showed an improvement in survival with Tukysa in a group of patients who had few alternative options. The company would need to provide final results of the main study to clarify the exact extent of the benefits. The reported side effects were considered manageable, and mostly related to effects on the gut. The Agency therefore decided that Tukysa's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Tukysa?

The company that markets Tukysa will provide final results from the main study showing the length of time patients live overall as well as without their disease getting worse.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tukysa have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Tukysa are continuously monitored. Side effects reported with Tukysa are carefully evaluated and any necessary action taken to protect patients.

## Other information about Tukysa

Tukysa received a marketing authorisation valid throughout the EU on 11 February 2021.

Tukysa : EPAR - Medicine overview

Reference Number: EMA/50289/2021

English (EN) (119.14 KB - PDF)

**First published:** 18/02/2021

[View](/en/documents/overview/tukysa-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-121)

български (BG) (134.18 KB - PDF)

**First published:**

18/02/2021

[View](/bg/documents/overview/tukysa-epar-medicine-overview_bg.pdf)

español (ES) (109.27 KB - PDF)

**First published:**

18/02/2021

[View](/es/documents/overview/tukysa-epar-medicine-overview_es.pdf)

čeština (CS) (132.98 KB - PDF)

**First published:**

18/02/2021

[View](/cs/documents/overview/tukysa-epar-medicine-overview_cs.pdf)

dansk (DA) (109.14 KB - PDF)

**First published:**

18/02/2021

[View](/da/documents/overview/tukysa-epar-medicine-overview_da.pdf)

Deutsch (DE) (113.15 KB - PDF)

**First published:**

18/02/2021

[View](/de/documents/overview/tukysa-epar-medicine-overview_de.pdf)

eesti keel (ET) (97.01 KB - PDF)

**First published:**

18/02/2021

[View](/et/documents/overview/tukysa-epar-medicine-overview_et.pdf)

ελληνικά (EL) (133.46 KB - PDF)

**First published:**

18/02/2021

[View](/el/documents/overview/tukysa-epar-medicine-overview_el.pdf)

français (FR) (110.85 KB - PDF)

**First published:**

18/02/2021

[View](/fr/documents/overview/tukysa-epar-medicine-overview_fr.pdf)

hrvatski (HR) (131.19 KB - PDF)

**First published:**

18/02/2021

[View](/hr/documents/overview/tukysa-epar-medicine-overview_hr.pdf)

italiano (IT) (108.39 KB - PDF)

**First published:**

18/02/2021

[View](/it/documents/overview/tukysa-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (137.4 KB - PDF)

**First published:**

18/02/2021

[View](/lv/documents/overview/tukysa-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (129.59 KB - PDF)

**First published:**

18/02/2021

[View](/lt/documents/overview/tukysa-epar-medicine-overview_lt.pdf)

magyar (HU) (129.83 KB - PDF)

**First published:**

18/02/2021

[View](/hu/documents/overview/tukysa-epar-medicine-overview_hu.pdf)

Malti (MT) (131.82 KB - PDF)

**First published:**

18/02/2021

[View](/mt/documents/overview/tukysa-epar-medicine-overview_mt.pdf)

Nederlands (NL) (110.19 KB - PDF)

**First published:**

18/02/2021

[View](/nl/documents/overview/tukysa-epar-medicine-overview_nl.pdf)

polski (PL) (134.69 KB - PDF)

**First published:**

18/02/2021

[View](/pl/documents/overview/tukysa-epar-medicine-overview_pl.pdf)

português (PT) (110.35 KB - PDF)

**First published:**

18/02/2021

[View](/pt/documents/overview/tukysa-epar-medicine-overview_pt.pdf)

română (RO) (127.83 KB - PDF)

**First published:**

18/02/2021

[View](/ro/documents/overview/tukysa-epar-medicine-overview_ro.pdf)

slovenčina (SK) (130.43 KB - PDF)

**First published:**

18/02/2021

[View](/sk/documents/overview/tukysa-epar-medicine-overview_sk.pdf)

slovenščina (SL) (129.22 KB - PDF)

**First published:**

18/02/2021

[View](/sl/documents/overview/tukysa-epar-medicine-overview_sl.pdf)

Suomi (FI) (105.98 KB - PDF)

**First published:**

18/02/2021

[View](/fi/documents/overview/tukysa-epar-medicine-overview_fi.pdf)

svenska (SV) (107.33 KB - PDF)

**First published:**

18/02/2021

[View](/sv/documents/overview/tukysa-epar-medicine-overview_sv.pdf)

Tukysa : EPAR - Risk management plan

English (EN) (1.57 MB - PDF)

**First published:** 18/02/2021

**Last updated:** 14/11/2025

[View](/en/documents/rmp/tukysa-epar-risk-management-plan_en.pdf)

## Product information

Tukysa : EPAR - Product information

English (EN) (545.72 KB - PDF)

**First published:** 18/02/2021

**Last updated:** 25/11/2025

[View](/en/documents/product-information/tukysa-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-383)

български (BG) (631.93 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/bg/documents/product-information/tukysa-epar-product-information_bg.pdf)

español (ES) (606.98 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/es/documents/product-information/tukysa-epar-product-information_es.pdf)

čeština (CS) (622.13 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/cs/documents/product-information/tukysa-epar-product-information_cs.pdf)

dansk (DA) (623.27 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/da/documents/product-information/tukysa-epar-product-information_da.pdf)

Deutsch (DE) (569.15 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/de/documents/product-information/tukysa-epar-product-information_de.pdf)

eesti keel (ET) (586.95 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/et/documents/product-information/tukysa-epar-product-information_et.pdf)

ελληνικά (EL) (644.85 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/el/documents/product-information/tukysa-epar-product-information_el.pdf)

français (FR) (652.23 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/fr/documents/product-information/tukysa-epar-product-information_fr.pdf)

hrvatski (HR) (631.85 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/hr/documents/product-information/tukysa-epar-product-information_hr.pdf)

íslenska (IS) (623.77 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/is/documents/product-information/tukysa-epar-product-information_is.pdf)

italiano (IT) (621.64 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/it/documents/product-information/tukysa-epar-product-information_it.pdf)

latviešu valoda (LV) (623.49 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/lv/documents/product-information/tukysa-epar-product-information_lv.pdf)

lietuvių kalba (LT) (629.32 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/lt/documents/product-information/tukysa-epar-product-information_lt.pdf)

magyar (HU) (631.57 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/hu/documents/product-information/tukysa-epar-product-information_hu.pdf)

Malti (MT) (610.77 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/mt/documents/product-information/tukysa-epar-product-information_mt.pdf)

Nederlands (NL) (623.56 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/nl/documents/product-information/tukysa-epar-product-information_nl.pdf)

norsk (NO) (595.75 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/no/documents/product-information/tukysa-epar-product-information_no.pdf)

polski (PL) (658.59 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/pl/documents/product-information/tukysa-epar-product-information_pl.pdf)

português (PT) (623.91 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/pt/documents/product-information/tukysa-epar-product-information_pt.pdf)

română (RO) (629.26 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/ro/documents/product-information/tukysa-epar-product-information_ro.pdf)

slovenčina (SK) (623.37 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/sk/documents/product-information/tukysa-epar-product-information_sk.pdf)

slovenščina (SL) (615.82 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/sl/documents/product-information/tukysa-epar-product-information_sl.pdf)

Suomi (FI) (602.96 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/fi/documents/product-information/tukysa-epar-product-information_fi.pdf)

svenska (SV) (607.53 KB - PDF)

**First published:**

18/02/2021

**Last updated:**

25/11/2025

[View](/sv/documents/product-information/tukysa-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000308552 24/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tukysa : EPAR - All authorised presentations

English (EN) (16.89 KB - PDF)

**First published:** 18/02/2021

[View](/en/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-365)

български (BG) (38.88 KB - PDF)

**First published:**

18/02/2021

[View](/bg/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_bg.pdf)

español (ES) (17.29 KB - PDF)

**First published:**

18/02/2021

[View](/es/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_es.pdf)

čeština (CS) (25.44 KB - PDF)

**First published:**

18/02/2021

[View](/cs/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (16.96 KB - PDF)

**First published:**

18/02/2021

[View](/da/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (17.1 KB - PDF)

**First published:**

18/02/2021

[View](/de/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (17.17 KB - PDF)

**First published:**

18/02/2021

[View](/et/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (39.44 KB - PDF)

**First published:**

18/02/2021

[View](/el/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_el.pdf)

français (FR) (17.13 KB - PDF)

**First published:**

18/02/2021

[View](/fr/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (25.48 KB - PDF)

**First published:**

18/02/2021

[View](/hr/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (16.84 KB - PDF)

**First published:**

18/02/2021

[View](/is/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_is.pdf)

italiano (IT) (17.28 KB - PDF)

**First published:**

18/02/2021

[View](/it/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (37.69 KB - PDF)

**First published:**

18/02/2021

[View](/lv/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (37.28 KB - PDF)

**First published:**

18/02/2021

[View](/lt/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (25.32 KB - PDF)

**First published:**

18/02/2021

[View](/hu/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (34.1 KB - PDF)

**First published:**

18/02/2021

[View](/mt/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (17.3 KB - PDF)

**First published:**

18/02/2021

[View](/nl/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (16.99 KB - PDF)

**First published:**

18/02/2021

[View](/no/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_no.pdf)

polski (PL) (26.63 KB - PDF)

**First published:**

18/02/2021

[View](/pl/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_pl.pdf)

português (PT) (16.87 KB - PDF)

**First published:**

18/02/2021

[View](/pt/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_pt.pdf)

română (RO) (35.86 KB - PDF)

**First published:**

18/02/2021

[View](/ro/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (25.85 KB - PDF)

**First published:**

18/02/2021

[View](/sk/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (24.3 KB - PDF)

**First published:**

18/02/2021

[View](/sl/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (17.11 KB - PDF)

**First published:**

18/02/2021

[View](/fi/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (17.07 KB - PDF)

**First published:**

18/02/2021

[View](/sv/documents/all-authorised-presentations/tukysa-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Tukysa Active substance tucatinib International non-proprietary name (INN) or common name tucatinib Therapeutic area (MeSH)

- Breast Neoplasms
- Neoplasm Metastasis

Anatomical therapeutic chemical (ATC) code L01EH03

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2?positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens.

## Authorisation details

EMA product number EMEA/H/C/005263

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Opinion adopted 10/12/2020 Marketing authorisation issued 11/02/2021 Revision 11

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tukysa : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (134.34 KB - PDF)

**First published:** 03/04/2025

**Last updated:** 25/11/2025

[View](/en/documents/procedural-steps-after/tukysa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Tukysa : EPAR - Procedural steps taken and scientific information after the authorisation (archive)

English (EN) (129.99 KB - PDF)

**First published:** 26/05/2021

**Last updated:** 03/04/2025

[View](/en/documents/procedural-steps-after/tukysa-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Tukysa-H-C-PSUSA-00010918-202204 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/93554/2023

English (EN) (121.29 KB - PDF)

**First published:** 27/02/2023

[View](/en/documents/scientific-conclusion/tukysa-h-c-psusa-00010918-202204-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Tukysa : EPAR - Public assessment report

Adopted

Reference Number: EMA/78409/2021

English (EN) (7.49 MB - PDF)

**First published:** 18/02/2021

[View](/en/documents/assessment-report/tukysa-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Tukysa

Adopted

Reference Number: EMA/CHMP/646289/2020

English (EN) (128.54 KB - PDF)

**First published:** 11/12/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-tukysa_en.pdf)

#### News on Tukysa

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020) 11/12/2020

#### More information on Tukysa

- [EMEA-002242-PIP02-21 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002242-pip02-21)

**This page was last updated on** 25/11/2025

## Share this page

[Back to top](#main-content)